BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cord blood » Page 5

Global Cord Blood Corporation (CO) Positioned to Merge with Cordlife Group in Asia

June 10, 2019 By Cade Hildreth (CEO) 1 Comment

GCBC Cordlife

Global Cord Blood Corporation (NYSE: CO) announced June 4, 2019, that its board of directors received a non-binding proposal letter from Cordlife Group Limited for the two companies to combine by way of a statutory merger. Under the terms of the nonbinding proposal, Cordlife will issue its ordinary shares at SGD0.5 per ordinary share, and in exchange, will receive all of the outstanding ordinary shares of Global Cord Blood Corporation (GCBC) at US$7.50 per share. [Read more…]

Filed Under: Cord Blood Tagged With: cord blood, cord tissue

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

June 4, 2019 By Cade Hildreth (CEO) Leave a Comment

ExCellThera ECT-001

MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]

Filed Under: Cell Therapy, Cord Blood, Press Releases Tagged With: cord blood, ExCellThera, RMAT

Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent

May 6, 2019 By Cade Hildreth (CEO) Leave a Comment

FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]

Filed Under: Cord Blood, Stem Cell News Tagged With: cord blood, Famicord, M&A

ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation

April 29, 2019 By Cade Hildreth (CEO) Leave a Comment

ExCellThera ECT-001

ExcelltheraMONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]

Filed Under: Cord Blood, Press Releases Tagged With: cord blood, ExCellThera

PBKM (Famicord) May Acquire Esperite NV (Cryo-Save) Stem Cell Banking Business

March 11, 2019 By Cade Hildreth (CEO) Leave a Comment

PBKM Famicord Esperite Cryo-Save

Amsterdam, the Netherlands – 22 February 2019 — Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are both leading in the stem cell banking sector. Cryo-Save is one of the largest and longest operating stem cell bank in Europe, in which store more than 330.000 umbilical cord blood samples and tissues. [Read more…]

Filed Under: Cord Blood Tagged With: cord blood, Esperite NV, Famicord

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 32
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    5段階中0の評価
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    5段階中0の評価
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    5段階中0の評価
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.